Bempedoic acid for high-risk patients with CVD as adjunct lipid-lowering therapy: A cost-effectiveness analysis

Lipid Lowering ◽

Lipid Lowering Therapy ◽

High Risk Patients ◽

Effectiveness Analysis ◽

Lowering Therapy ◽

PIN1 COST-EFFECTIVENESS ANALYSIS OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE FOR HIGH RISK PATIENTS IN THE PERSPECTIVE OF BRAZILIAN NIP

Value in Health Regional Issues ◽

10.1016/j.vhri.2019.08.232 ◽

2019 ◽

Vol 19 ◽

pp. S40

Author(s):

R.F. Alexandre ◽

C. Salgado De Santana ◽

T. Senna ◽

J. Spinardi ◽

R. Sini

Keyword(s):

Cost Effectiveness ◽

High Risk ◽

Conjugate Vaccine ◽

Pneumococcal Conjugate Vaccine ◽

High Risk Patients ◽

Effectiveness Analysis ◽

Effective Lipid-lowering Therapy in High-risk Patients

European Journal of Cardiovascular Medicine ◽

10.5083/ejcm.20424884.211 ◽

2011 ◽

Vol 1 (111) ◽

Author(s):

John J.P. Kastelein ◽

Benoit J Arsenault ◽

Jean-Claude Tardif

Keyword(s):

High Risk ◽

Lipid Lowering ◽

Lipid Lowering Therapy ◽

High Risk Patients ◽

Lowering Therapy ◽

The Effect of Switching to the High-Efficient Rosuvastatin on the Success of Lipid Lowering Therapy in High Risk Patients. The CORVUS (Controlled Targets for High Vascular Risk Patients Using Effective Statins) Study

Pharmaceutica Analytica Acta ◽

10.4172/2153-2435.1000267 ◽

2013 ◽

Vol 04 (08) ◽

Author(s):

Istvan Reiber

Keyword(s):

High Risk ◽

Lipid Lowering ◽

Lipid Lowering Therapy ◽

Vascular Risk ◽

High Risk Patients ◽

Lowering Therapy ◽

High Efficient ◽

A COST EFFECTIVENESS ANALYSIS (CEA) COMPARING THE PURE-VU SYSTEM TO STANDARD COLONOSCOPY IN AVERAGE AND HIGH-RISK PATIENTS PRESENTING WITH INADEQUATELY PREPPED COLONS

10.1055/s-0040-1704802 ◽

2020 ◽

Author(s):

I Gralnek ◽

J Voigt ◽

S Nussbaum

Keyword(s):

Cost Effectiveness ◽

High Risk ◽

High Risk Patients ◽

Effectiveness Analysis ◽

Risk Patients ◽

Standard Colonoscopy

Cost-Effectiveness Analysis of Invasive and Noninvasive Tests in High Risk Patients Treated With Amiodarone After Acute Myocardial Infarction

Journal of the American College of Cardiology ◽

10.1016/s0735-1097(98)00171-5 ◽

1998 ◽

Vol 31 (7) ◽

pp. 1481-1489 ◽

Cited By ~ 3

Author(s):

Roberto F.E Pedretti ◽

Giovanni B Migliori ◽

Vittorio Mapelli ◽

Gabriele Daniele ◽

Philip J Podrid ◽

...

Keyword(s):

Myocardial Infarction ◽

Acute Myocardial Infarction ◽

Cost Effectiveness ◽

High Risk ◽

High Risk Patients ◽

Effectiveness Analysis ◽

Risk Patients ◽

Noninvasive Tests

PCV74 Treatment Patterns and LDL-C Control in VERY High-Risk Patients Receiving Lipid-Lowering Therapy in the United Kingdom

Value in Health ◽

10.1016/j.jval.2020.08.565 ◽

2020 ◽

Vol 23 ◽

pp. S499-S500

Author(s):

Y. Beaini ◽

M. Danese ◽

E. Sidelnikov ◽

G. Villa ◽

D. Catterick ◽

...

Keyword(s):

United Kingdom ◽

High Risk ◽

Treatment Patterns ◽

Lipid Lowering ◽

Lipid Lowering Therapy ◽

High Risk Patients ◽

The United Kingdom ◽

Lowering Therapy ◽

Risk Patients ◽

Very High

The changing landscape of lipid-lowering therapy after the new ESC/EAS guidelines for the management of dyslipidaemias: Launching the era of triple hypolipidaemic therapy in very high risk patients

Atherosclerosis ◽

10.1016/j.atherosclerosis.2019.11.009 ◽

2020 ◽

Vol 292 ◽

pp. 231-233 ◽

Cited By ~ 4

Author(s):

Loukianos S. Rallidis

Keyword(s):

High Risk ◽

Lipid Lowering ◽

Lipid Lowering Therapy ◽

High Risk Patients ◽

Lowering Therapy ◽

Risk Patients ◽

Very High

Lipid-lowering therapy with PCSK9-inhibitors in the management of cardiovascular high-risk patients: Effectiveness, therapy adherence and safety in a real world cohort

Cardiology Journal ◽

10.5603/cj.a2017.0137 ◽

2018 ◽

Vol 25 (1) ◽

pp. 32-41 ◽

Cited By ~ 12

Author(s):

Michael Saborowski ◽

Michael Dölle ◽

Michael P. Manns ◽

Holger Leitolf ◽

Steffen Zender

Keyword(s):

High Risk ◽

Real World ◽

Lipid Lowering ◽

Lipid Lowering Therapy ◽

Pcsk9 Inhibitors ◽

Therapy Adherence ◽

High Risk Patients ◽

Lowering Therapy ◽

Cost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent Clostridium difficile Infection in High-Risk Patients in Spain

Advances in Therapy ◽

10.1007/s12325-018-0813-y ◽

2018 ◽

Vol 35 (11) ◽

pp. 1920-1934 ◽

Cited By ~ 4

Author(s):

Miguel Salavert ◽

Javier Cobo ◽

Álvaro Pascual ◽

Belén Aragón ◽

Stefano Maratia ◽

...

Keyword(s):

Cost Effectiveness ◽

High Risk ◽

Clostridium Difficile ◽

Clostridium Difficile Infection ◽

Standard Of Care ◽

High Risk Patients ◽

Recurrent Clostridium Difficile Infection ◽

Effectiveness Analysis ◽

PST3 CLOPIDOGREL VERSUS ASPIRIN IN HIGH-RISK PATIENTS WITH RECENT ISCHEMIC STROKE ORTRANSIENT ISCHEMIC ATTACK: COST-EFFECTIVENESS ANALYSIS IN ITALY

Value in Health ◽

10.1016/s1098-3015(10)67612-7 ◽

2005 ◽

Vol 8 (6) ◽

pp. A151

Author(s):

G Rudelli ◽

S Roze ◽

AJ Palmer ◽

Z Hakimi ◽

J Spiesser ◽

...

Keyword(s):

Ischemic Stroke ◽

Cost Effectiveness ◽

High Risk ◽

High Risk Patients ◽

Effectiveness Analysis ◽

Risk Patients ◽

Ischemic Attack